{
  "docId": "019de511-345d-7570-a494-480f2370811c",
  "docSlug": "ec9eb0ed92f9fb3cafb36e44028c44da",
  "documentTitle": "MaxCyte | IPO Presentation Deck | 34 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 4,
  "pageCount": 34,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de511-345d-7570-a494-480f2370811c/4",
  "deckHref": "/decks/019de511-345d-7570-a494-480f2370811c",
  "deckJsonHref": "/decks/019de511-345d-7570-a494-480f2370811c.json",
  "deckAnchorHref": "/decks/019de511-345d-7570-a494-480f2370811c#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.03,
        "y": 0.45
      },
      "kind": "list",
      "text": "Enables delivery of almost any molecule into almost any cell type; Leads the industry in performance; Extensive product portfolio; ~23% 5-year CAGR of organic revenue growth; pharmaceutical-level gross margins of ~89%",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c130172-20fa-429e-a78a-4816f5ac8b0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.67,
        "y": 0.45
      },
      "kind": "list",
      "text": "Allows MaxCyte to participate in the value created by our partners' programs; 13 Strategic Platform Licenses (SPLs), which include over $950m in potential pre-commercial milestone payments; Focused over the long-term on creating a diverse portfolio",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6dca38f3-e5c1-44d2-9c8a-c8a6c2028a03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.35,
        "y": 0.2
      },
      "kind": "list",
      "text": "Leading the growing next-generation cell therapy market and capitalize on rising demand for non-viral engineering approaches",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bf6769f-be27-426f-843f-6a36c491fa4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "list",
      "text": "With 400+ platforms in place, our proprietary technology platform unlocks the significant potential of advanced therapeutics",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aca56e4a-fafc-491e-8e4f-4f881623f3b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "list",
      "text": "20+ years of cell engineering expertise; 20+ field sales and application scientists; Significant number of collaborations; Supported by our FDA Master File and International Technical Files; referenced in over 30 clinical trials",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d99413c8-c53d-40f1-80b2-0dc33eee26c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.67,
        "y": 0.2
      },
      "kind": "list",
      "text": "Innovative business model focused on value creation and shared partnership success",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5803010-9953-4f4c-84da-b72f7636c35d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "A Leading Provider of Cell-engineering Platform",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9916c65b-99ef-47aa-894d-86b86ed74c69",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "a5155e13-21a8-49a4-b7ad-29ee1a98fdcd",
      "evidence": "Allows MaxCyte to participate in the value created by our partners' programs; 13 Strategic Platform Licenses (SPLs), which include over $950m in potential pre-commercial milestone payments;",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 6,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "60446270-f722-4357-a48b-406a48bf1079",
      "evidence": "Slides 4-6 present the executive summary and leadership team.",
      "position": 0,
      "objective": "Why MaxCyte's platform is valuable",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}